Normal View Dyslexic View
Pathogens, antibodies and graft fate: a translational perspective on pseudomonas aeruginosa in lung transplantation
Related articles
Faecal microbiota transplantation unravelled
Hugo Armand Roberto Sivov BA&Sc1, Florine Helene Zwezerijnen-Jiwa MD1,2,3, James Kinross MD, PhD1,*
1Department of Surgery and Cancer, St. Mary’s Hospital, Imperial College London, London W2 1NY, UK
2Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology and Metabolism, Academic Medical Center, University of Amsterdam, 1105 BK Amsterdam, The Netherlands
3Department of Gastroenterology, Amsterdam Medical Centres, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
*Corresponding Author:
Dr. James Kinross, department of Surgery and Cancer, St. Mary’s Hospital, Imperial College London, 10th Floor QEQMW, Praed Street, London, W2 1NY, UK
Funding Sources: Marie-Skłodowska-Curie grant agreement no. 814168.
Article Review Schmidt TSB, Li SS, Maistrenko OM, et al. Drivers and determinants of strain dynamics following fecal microbiota transplantation. Nature Medicine (2022). 28(9), 1902-1912 Faecal microbiota transplantation (FMT) is currently recommended in the UK by the National Institute for Health and Care Excellence (NICE) for the treatment of recurrent Clostridioidesdifficile infection (rCDI)1. Additionally, FMT is being extensively investigated for its potential application in surgical diseases, like the prevention of anastomotic leak2, as well as in ulcerative colitis (UC) and its related surgical complications, such as pouchitis3. Modulation of the faecal microbiome has significant implications for surgeons, as emerging evidence suggests pre-operative optimisation of the gut microbiota enhances patient outcomes and reduces surgical risks, such as surgical site infection, postoperative ileus and anastomotic leak4, 5, 6.